This is where the appointment of IQVIA last year was a very critical forward planning move my OSL to hopefully nail home the final approval process. I am guessing that OSL will now have their post approval ducks all lined up.
From the 30th of August 2018 announcement last year.
Key highlights
Appointment of IQVIA as EU Market Access and Reimbursement Advisor represents a significant milestone for the Company commercialisation strategy
IQVIA will work in collaboration with the Company to develop a strategic and effective approach to commercialisation of the OncoSilTM device in key EU Markets
IQVIA is a globally recognised leader in the provision of information, technology solutions and contract research services in the healthcare sector and brings deep experience commercialising breakthrough technologies
Appointment of IQVIA accelerates path to early commercialisation of OncoSil device
Ann: Positive CE Mark Status Report, page-14
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
-0.001(12.5%) |
Mkt cap ! $31.31M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 0.8¢ | 0.7¢ | $69.42K | 8.685M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 67 | 28673846 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 7597003 | 11 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| OSL (ASX) Chart |